Tech Company Financing Transactions
NervGen Pharma Funding Round
PFP Biosciences joined a $15 million funding round for NervGen Pharma. The round was announced on 7/14/2022.
Transaction Overview
Company Name
Announced On
7/14/2022
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Undisclosed
Investors
PFP Biosciences (Adam Rogers)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2955 Virtual Way 480
Vancouver BC, V5M 4X6
Canada
Vancouver BC, V5M 4X6
Canada
Phone
Website
Email Address
Overview
NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial focus is on Alzheimer's, spinal cord injury and multiple sclerosis.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Paul Brennan
Chief Financial Officer
Bill Adams
Chief Medical Officer
Dan Mikol
Vice President
Nana Collett
Browse more venture capital transactions:
Prev: 7/14/2022: Bobidi venture capital transaction
Next: 7/14/2022: Lightyear Financial venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs